Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bally's (BALY) Asset Writedowns and Impairment (2018 - 2025)

Bally's (BALY) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $236.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Asset Writedowns and Impairment rose 68.45% to $236.1 million in Q4 2024 year-over-year; TTM through Sep 2025 was $376.3 million, a 151.16% increase, with the full-year FY2024 number at $248.9 million, up 66.11% from a year prior.
  • Asset Writedowns and Impairment was $236.1 million for Q4 2024 at Bally's, up from $140.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $464.0 million in Q4 2022 to a low of $59000.0 in Q4 2020.
  • A 5-year average of $107.9 million and a median of $8.5 million in 2020 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 143.7% in 2020, then crashed 69.79% in 2023.
  • Bally's' Asset Writedowns and Impairment stood at $59000.0 in 2020, then skyrocketed by 7823.73% to $4.7 million in 2021, then skyrocketed by 9824.66% to $464.0 million in 2022, then plummeted by 69.79% to $140.2 million in 2023, then skyrocketed by 68.45% to $236.1 million in 2024.
  • Per Business Quant, the three most recent readings for BALY's Asset Writedowns and Impairment are $236.1 million (Q4 2024), $140.2 million (Q4 2023), and $9.7 million (Q2 2023).